



**WIPO Global Challenges Seminar:
Urgent Innovation: Policies and
Practices for Effective Response to
Global Health Crises**

16 April 2019


Michelle Childs
Global Head of Policy Advocacy

DNDi's success is only possible through innovative partnerships

Over 160 partnerships worldwide

CRITERIA FOR SUCCESS

- ✓ Share the same vision
- ✓ Mutual understanding
- ✓ Involvement throughout the whole process



IP & Access: DNDi vision


Affordable treatment and equitable access to patients in need

- Delinking the costs of R&D from the price of products
- DNDi activities not financed by IP revenues
- No partnership without overcoming IP barriers which could prevent access

Develop drugs as public goods, when possible

- Disseminate the results of DNDi work
- Encourage open publication of research data and technology transfer
- Decisions regarding ownership of patents and licensing terms made on a case-by-case basis

DNDI's R&D and Access strategies



- Target Product Profiles: needs, acceptability, safety, quality, **end-price**
- Stakeholder involvement and public leadership from the beginning
- **Open, collaborative, drug discovery**


- **Licensing terms that reduce bottlenecks, and allow access to knowledge and medicines**
- Multisectoral stakeholder platforms
- Clinical capacity-building in public and private sector

- Adapted regulatory approaches
- Enable access and scale-up through working with treatment providers and communities
- Updated evidence-based guidance
- Technology transfer

Pandemic Response Box (PRB) - MMV and DNDi


- **Concept:** To provide free-to-access first-line screening compounds for use in addressing future pandemic outbreaks
 - Complimentary to the existing toolboxes from MMV (e.g. Pathogen Box, Malaria Box)
 - Collection of known antibacterials, antifungals and antivirals
 - 400 diverse compounds selected based on diversity of target pathogen and mechanism of action
 - Obligation: Screening results publicly available, publish in open access journal
 - Launched Jan 2019 >35 requests for copy of the box to date

The screenshot shows the MMV (Medicines for Malaria Venture) website. The header includes the MMV logo and the tagline "Developing antimalarials to save lives". The navigation menu includes "Research & Development", "Access", "Partnering", "Our impact", "About us", "Malaria & medicines", and "Newsroom". The main content area is titled "About the Pandemic Response Box" and features a sidebar with links such as "Request the Pandemic Response Box", "Supporting information", and "Terms & conditions". The main text describes the PRB as a collection of 400 diverse drug-like molecules active against bacteria, viruses, or fungi, available free of charge. It also includes a small image of the PRB box and a paragraph explaining the rationale for its creation.



NTD Drug Discovery Booster



DNDi
Drugs for Neglected Diseases initiative





Identify new molecule of interest with moderate antiparasitic activity



Mine proprietary collections of millions of compounds to find "similar" structures



Test compounds for anti-parasitic activity




Feedback results to improve the mining process

- Speeds up the process. Cheaper : Est USD 90,000 saving per iteration
- Four hit series approved already
- Opens doors into previously inaccessible «proprietary» chemical space
- Engages cutting edge science and scientists
- Publication of results by DNDi instead of patent filing. Royalty-free licenses granted to DNDi on pre-existing IP for use in NTDs

A pan-genotypic HCV treatment- Wide access licence

- DNDi, Pharco and Presidio agreement to test combination of sofosbuvir + ravidasvir
- Partnership with Malaysia and Thailand to conduct Phase II/III multicentre study
- Using innovative licensing agreement or TRIPS flexibilities
- Ravidasvir licence includes all MICs



Downstream:

8 new treatments delivered since 2007



- ✓ Easy to use
- ✓ Affordable
- ✓ Field-adapted
- ✓ Non-patented



2007 **ASAQ**
Malaria
>500 million patients reached



2008 **ASMQ**
Malaria
Used in Africa and Asia



2009 **NECT**
Sleeping sickness
100% of stage-2 patients



2010 **SSG&PM**
Visceral leishmaniasis in E Africa
Now 1st line in all countries




2011 **PAEDIATRIC BENZNIDAZOLE**
Chagas disease
Two sources developed



2011 **NEW VL TREATMENT ASIA**
Visceral leishmaniasis in Asia
Support to disease elimination



2016 **SUPERBOOSTER THERAPY**
Paediatric HIV
Recommended by WHO



2018 **FEXINIDAZOLE**
Sleeping sickness
Approved by European Medicines Agency, first all-oral treatment


NEW!



THANK YOU

TO ALL OUR
PARTNERS &
DONORS

DNDi
Drugs for Neglected Diseases initiative



Ministry of Foreign Affairs of the Netherlands



through **KFW**

